{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:57:18Z","timestamp":1792166238180,"version":"4.4.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","award":["21156"],"award-info":[{"award-number":["21156"]}],"id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Mesenchymal stem or stromal cells are the most widely used cell therapy to date. They are heterogeneous, with variations in growth potential, differentiation capacity and protein expression profile depending on tissue source and production process. Nomenclature and defining characteristics have been debated for almost 20 years, yet the generic term \u2018MSC\u2019 is used to cover a wide range of cellular phenotypes. Against a documented lack of definition of cellular populations used in clinical trials, our study evaluated the extent of characterisation of the cellular population or study drug.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A literature search of clinical trials involving mesenchymal stem\/stromal cells was refined to 84 papers upon application of pre-defined inclusion\/exclusion criteria. Data were extracted covering background trial information including location, phase, indication, tissue source and details of clinical cell population characterisation (expression of surface markers, viability, differentiation assays and potency\/functionality assays). Descriptive statistics were applied, and tests of association between groups were explored using Fisher\u2019s exact test for count data with simulated p value.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-eight studies (33.3%) include no characterisation data. Forty-five (53.6%) reported average values per marker for all cell lots used in the trial, and 11 (13.1%) studies included individual values per cell lot. Viability was reported in 57% of studies. Differentiation was discussed: osteogenesis (29% of papers), adipogenesis (27%), and chondrogenesis (20%) and other functional assays arose in 7 papers (8%). The extent of characterisation was not related to the clinical phase of development. Assessment of functionality was very limited and did not always relate to the likely mechanism of action.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The extent of characterisation was poor and variable. Our findings concur with those in other fields including bone marrow aspirate and platelet-rich plasma therapy. We discuss the potential implications of these findings for the use of mesenchymal stem or stromal cells in regenerative medicine, and the importance of characterisation for transparency and comparability of literature.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s13287-021-02435-1","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T12:14:52Z","timestamp":1624364092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Characterisation of mesenchymal stromal cells in clinical trial reports: analysis of published descriptors"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9438-7802","authenticated-orcid":false,"given":"Alison J.","family":"Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Rand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Genever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"issue":"6","key":"2435_CR1","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","volume":"22","author":"J Galipeau","year":"2018","unstructured":"Galipeau J, Sens\u00e9b\u00e9 L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824\u201333. https:\/\/doi.org\/10.1016\/j.stem.2018.05.004.","journal-title":"Cell Stem Cell"},{"key":"2435_CR2","doi-asserted-by":"crossref","unstructured":"Rousseau CF, Ma\u010diulaitis R, \u015aladowski D, Narayanan G. Cell and gene therapies: European view on challenges in translation and how to address them. Front Med (Lausanne). 2018;5(158):1\u20136.","DOI":"10.3389\/fmed.2018.00158"},{"key":"2435_CR3","doi-asserted-by":"publisher","first-page":"9628536","DOI":"10.1155\/2019\/9628536","volume":"2019","author":"B Lukomska","year":"2019","unstructured":"Lukomska B, et al. Challenges and controversies in human mesenchymal stem cell therapy. Stem Cells International. 2019;2019:9628536.","journal-title":"Stem Cells International"},{"issue":"7382","key":"2435_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature10783","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature. 2012;481(7382):457\u201362. https:\/\/doi.org\/10.1038\/nature10783.","journal-title":"Nature"},{"issue":"2","key":"2435_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.stem.2014.06.008","volume":"15","author":"BO Zhou","year":"2014","unstructured":"Zhou BO, Yue R, Murphy MM, Peyer JG, Sean J. Morrison, Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell. 2014;15(2):154\u201368. https:\/\/doi.org\/10.1016\/j.stem.2014.06.008.","journal-title":"Cell Stem Cell"},{"issue":"7308","key":"2435_CR6","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nature09262","volume":"466","author":"S M\u00e9ndez-Ferrer","year":"2010","unstructured":"M\u00e9ndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, MacArthur BD, Lira SA, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466(7308):829\u201334. https:\/\/doi.org\/10.1038\/nature09262.","journal-title":"Nature"},{"issue":"2","key":"2435_CR7","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cell.2007.08.025","volume":"131","author":"B Sacchetti","year":"2007","unstructured":"Sacchetti B, Funari A, Michienzi S, di Cesare S, Piersanti S, Saggio I, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell. 2007;131(2):324\u201336. https:\/\/doi.org\/10.1016\/j.cell.2007.08.025.","journal-title":"Cell"},{"issue":"1","key":"2435_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1478-811X-9-12","volume":"9","author":"R Hass","year":"2011","unstructured":"Hass R, Kasper C, B\u00f6hm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal. 2011;9(1):12. https:\/\/doi.org\/10.1186\/1478-811X-9-12.","journal-title":"Cell Commun Signal"},{"key":"2435_CR9","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1634\/stemcells.2005-0342","volume":"24","author":"S Kern","year":"2009","unstructured":"Kern S, Eichler H, Stoeve J, Kl\u00fcter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2009;24:1294\u2013301.","journal-title":"Stem Cells"},{"issue":"19","key":"2435_CR10","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1089\/scd.2013.0016","volume":"22","author":"H Wegmeyer","year":"2013","unstructured":"Wegmeyer H, Br\u00f6ske AM, Leddin M, Kuentzer K, Nisslbeck AK, Hupfeld J, et al. Mesenchymal stromal cell characteristics vary depending on their origin. Stem Cells Dev. 2013;22(19):2606\u201318. https:\/\/doi.org\/10.1089\/scd.2013.0016.","journal-title":"Stem Cells Dev"},{"issue":"6","key":"2435_CR11","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.stemcr.2015.05.005","volume":"4","author":"S James","year":"2015","unstructured":"James S, Fox J, Afsari F, Lee J, Clough S, Knight C, et al. Multiparameter analysis of human bone marrow stromal cells identifies distinct immunomodulatory and differentiation-competent subtypes. Stem Cell Rep. 2015;4(6):1004\u201315. https:\/\/doi.org\/10.1016\/j.stemcr.2015.05.005.","journal-title":"Stem Cell Rep"},{"key":"2435_CR12","doi-asserted-by":"publisher","first-page":"7232717","DOI":"10.1155\/2018\/7232717","volume":"2018","author":"P Mart\u00ednez-Peinado","year":"2018","unstructured":"Mart\u00ednez-Peinado P, Pascual-Garc\u00eda S, Roche E, Sempere-Ortells JM. Differences of clonogenic mesenchymal stem cells on immunomodulation of lymphocyte subsets. J Immunol Res. 2018;2018:7232717.","journal-title":"J Immunol Res"},{"issue":"4","key":"2435_CR13","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/stem.312","volume":"28","author":"KC Russell","year":"2010","unstructured":"Russell KC, Phinney DG, Lacey MR, Barrilleaux BL, Meyertholen KE, O'Connor KC. In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment. Stem Cells. 2010;28(4):788\u201398. https:\/\/doi.org\/10.1002\/stem.312.","journal-title":"Stem Cells"},{"issue":"5","key":"2435_CR14","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/stem.2296","volume":"34","author":"DA Rennerfeldt","year":"2016","unstructured":"Rennerfeldt DA, Van Vliet KJ. Concise review: when colonies are not clones: evidence and implications of intracolony heterogeneity in mesenchymal stem cells. Stem Cells. 2016;34(5):1135\u201341. https:\/\/doi.org\/10.1002\/stem.2296.","journal-title":"Stem Cells"},{"issue":"8","key":"2435_CR15","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1089\/ten.tea.2010.0216","volume":"16","author":"AI Caplan","year":"2010","unstructured":"Caplan AI. What\u2019s in a name? Tissue Eng Part A. 2010;16(8):2415\u20137. https:\/\/doi.org\/10.1089\/ten.tea.2010.0216.","journal-title":"Tissue Eng Part A"},{"issue":"6","key":"2435_CR16","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1002\/sctm.17-0051","volume":"6","author":"AI Caplan","year":"2017","unstructured":"Caplan AI. Mesenchymal stem cells: time to change the name! STEM CELLS Transl Med. 2017;6(6):1445\u201351. https:\/\/doi.org\/10.1002\/sctm.17-0051.","journal-title":"STEM CELLS Transl Med"},{"issue":"3","key":"2435_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/sj.clpt.6100313","volume":"82","author":"DJ Prockop","year":"2007","unstructured":"Prockop DJ. \u201cStemness\u201d does not explain the repair of many tissues by mesenchymal stem\/multipotent stromal cells (MSCs). Clin Pharmacol Ther. 2007;82(3):241\u20133. https:\/\/doi.org\/10.1038\/sj.clpt.6100313.","journal-title":"Clin Pharmacol Ther"},{"key":"2435_CR18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/d41586-018-06756-9","volume":"561","author":"D Sipp","year":"2018","unstructured":"Sipp D, Robey P, Turner L. Clear up this stem-cell mess. Nature. 2018;561:455\u20137.","journal-title":"Nature"},{"issue":"6","key":"2435_CR19","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2217\/rme-2018-0145","volume":"14","author":"A Wilson","year":"2019","unstructured":"Wilson A, Webster A, Genever P. Nomenclature and heterogeneity: consequences for the use of mesenchymal stem cells in regenerative medicine. Regen Med. 2019;14(6):595\u2013611. https:\/\/doi.org\/10.2217\/rme-2018-0145.","journal-title":"Regen Med"},{"issue":"2","key":"2435_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s12015-011-9312-0","volume":"8","author":"M Abumaree","year":"2012","unstructured":"Abumaree M, Al Jumah M, Pace RA, Kalionis B. Immunosuppressive properties of mesenchymal stem cells. Stem Cell Rev. 2012;8(2):375\u201392. https:\/\/doi.org\/10.1007\/s12015-011-9312-0.","journal-title":"Stem Cell Rev"},{"issue":"5-6","key":"2435_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cytogfr.2009.10.002","volume":"20","author":"L da Silva Meirelles","year":"2009","unstructured":"da Silva Meirelles L, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009;20(5-6):419\u201327. https:\/\/doi.org\/10.1016\/j.cytogfr.2009.10.002.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"11","key":"2435_CR22","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/sctm.19-0044","volume":"8","author":"I Mastrolia","year":"2019","unstructured":"Mastrolia I, Foppiani EM, Murgia A, Candini O, Samarelli AV, Grisendi G, et al. Challenges in clinical development of mesenchymal stromal\/stem cells: concise review. Stem Cells Transl Med. 2019;8(11):1135\u201348. https:\/\/doi.org\/10.1002\/sctm.19-0044.","journal-title":"Stem Cells Transl Med"},{"key":"2435_CR23","doi-asserted-by":"publisher","unstructured":"Caplan H, Olson SD, Kumar A, George M, Prabhakara KS, Wenzel P, et al. Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application. Front Immunol. 2019;10. https:\/\/doi.org\/10.3389\/fimmu.2019.01645.","DOI":"10.3389\/fimmu.2019.01645"},{"issue":"12","key":"2435_CR24","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/sctm.17-0129","volume":"6","author":"RM Samsonraj","year":"2017","unstructured":"Samsonraj RM, Raghunath M, Nurcombe V, Hui JH, van Wijnen AJ, Cool SM. Concise review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl Med. 2017;6(12):2173\u201385. https:\/\/doi.org\/10.1002\/sctm.17-0129.","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"2435_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4103\/1673-5374.264455","volume":"15","author":"FG Teixeira","year":"2020","unstructured":"Teixeira FG, Salgado AJ. Mesenchymal stem cells secretome: current trends and future challenges. Neural Regen Res. 2020;15(1):75\u20137. https:\/\/doi.org\/10.4103\/1673-5374.264455.","journal-title":"Neural Regen Res"},{"key":"2435_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41536-019-0083-6","volume":"4","author":"MF Pittenger","year":"2019","unstructured":"Pittenger MF, et al. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med. 2019;4:22.","journal-title":"NPJ Regen Med"},{"issue":"480","key":"2435_CR27","doi-asserted-by":"publisher","first-page":"eaat2189","DOI":"10.1126\/scitranslmed.aat2189","volume":"11","author":"I Martin","year":"2019","unstructured":"Martin I, Galipeau J, Kessler C, Le Blanc K, Dazzi F. Challenges for mesenchymal stromal cell therapies. Sci Transl Med. 2019;11(480):eaat2189. https:\/\/doi.org\/10.1126\/scitranslmed.aat2189.","journal-title":"Sci Transl Med"},{"issue":"5","key":"2435_CR28","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.stemcr.2017.03.013","volume":"8","author":"M Fung","year":"2017","unstructured":"Fung M, Yuan Y, Atkins H, Shi Q, Bubela T. Responsible translation of stem cell research: an assessment of clinical trial registration and publications. Stem Cell Rep. 2017;8(5):1190\u2013201. https:\/\/doi.org\/10.1016\/j.stemcr.2017.03.013.","journal-title":"Stem Cell Rep"},{"issue":"6","key":"2435_CR29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.stemcr.2016.05.001","volume":"6","author":"G Daley","year":"2016","unstructured":"Daley G, et al. Setting global standards for stem cell research and clinical translation: the 2016 ISSCR guidelines. Stem Cell Rep. 2016;6(6):787\u201397. https:\/\/doi.org\/10.1016\/j.stemcr.2016.05.001.","journal-title":"Stem Cell Rep"},{"issue":"18","key":"2435_CR30","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.2106\/JBJS.15.01495","volume":"98","author":"J Chahla","year":"2016","unstructured":"Chahla J, Piuzzi NS, Mitchell JJ, Dean CS, Pascual-Garrido C, LaPrade RF, et al. Intra-articular cellular therapy for osteoarthritis and focal cartilage defects of the knee: a systematic review of the literature and study quality analysis. J Bone Joint Surg Am. 2016;98(18):1511\u201321. https:\/\/doi.org\/10.2106\/JBJS.15.01495.","journal-title":"J Bone Joint Surg Am"},{"issue":"10","key":"2435_CR31","doi-asserted-by":"publisher","first-page":"904","DOI":"10.2106\/JBJS.18.00915","volume":"101","author":"IR Murray","year":"2019","unstructured":"Murray IR, Chahla J, Safran MR, Krych AJ, Saris DBF, Caplan AI, et al. International expert consensus on a cell therapy communication tool: DOSES. JBJS. 2019;101(10):904\u201311. https:\/\/doi.org\/10.2106\/JBJS.18.00915.","journal-title":"JBJS"},{"issue":"20","key":"2435_CR32","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.2106\/JBJS.16.01374","volume":"99","author":"J Chahla","year":"2017","unstructured":"Chahla J, Cinque ME, Piuzzi NS, Mannava S, Geeslin AG, Murray IR, et al. A call for standardization in platelet-rich plasma preparation protocols and composition reporting: a systematic review of the clinical orthopaedic literature. J Bone Joint Surg Am. 2017;99(20):1769\u201379. https:\/\/doi.org\/10.2106\/JBJS.16.01374.","journal-title":"J Bone Joint Surg Am"},{"issue":"10","key":"2435_CR33","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2106\/JBJS.16.00793","volume":"99","author":"IR Murray","year":"2017","unstructured":"Murray IR, Geeslin AG, Goudie EB, Petrigliano FA, LaPrade RF. Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO): platelet-rich plasma and mesenchymal stem cells. J Bone Joint Surg Am. 2017;99(10):809\u201319. https:\/\/doi.org\/10.2106\/JBJS.16.00793.","journal-title":"J Bone Joint Surg Am"},{"issue":"6","key":"2435_CR34","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2106\/JBJS.17.00451","volume":"100","author":"NS Piuzzi","year":"2018","unstructured":"Piuzzi NS, Hussain ZB, Chahla J, Cinque ME, Moatshe G, Mantripragada VP, et al. Variability in the preparation, reporting, and use of bone marrow aspirate concentrate in musculoskeletal disorders: a systematic review of the clinical orthopaedic literature. J Bone Joint Surg Am. 2018;100(6):517\u201325. https:\/\/doi.org\/10.2106\/JBJS.17.00451.","journal-title":"J Bone Joint Surg Am"},{"key":"2435_CR35","doi-asserted-by":"publisher","first-page":"8031718","DOI":"10.1155\/2018\/8031718","volume":"2018","author":"REB Fitzsimmons","year":"2018","unstructured":"Fitzsimmons REB, Mazurek MS, Soos A, Simmons CA. Mesenchymal stromal\/stem cells in regenerative medicine and tissue engineering. Stem Cells International. 2018;2018:8031718.","journal-title":"Stem Cells International"},{"key":"2435_CR36","unstructured":"Eudralex. 2007. http:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:L:2007:324:0121:0137:en:PDF. Accessed 5 Oct 2020."},{"key":"2435_CR37","unstructured":"FDA, in 21CFR1271.10, U. D. o. H. a. H. Services, Ed. (https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfCFR\/CFRSearch.cfm?fr=1271.10).\u00a0Accessed 7 Oct 2020."},{"issue":"1","key":"2435_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2217\/rme-2017-0115","volume":"13","author":"PS Knoepfler","year":"2018","unstructured":"Knoepfler PS, Turner LG. The FDA and the US direct-to-consumer marketplace for stem cell interventions: a temporal analysis. Regen Med. 2018;13(1):19\u201327. https:\/\/doi.org\/10.2217\/rme-2017-0115.","journal-title":"Regen Med"},{"issue":"11","key":"2435_CR39","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1136\/medethics-2016-104046","volume":"43","author":"T Lysaght","year":"2017","unstructured":"Lysaght T, Lipworth W, Hendl T, Kerridge I, Lee TL, Munsie M, et al. The deadly business of an unregulated global stem cell industry. J Med Ethics. 2017;43(11):744\u20136. https:\/\/doi.org\/10.1136\/medethics-2016-104046.","journal-title":"J Med Ethics"},{"issue":"11","key":"2435_CR40","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/emboj.2013.114","volume":"32","author":"P Bianco","year":"2013","unstructured":"Bianco P, Barker R, Br\u00fcstle O, Cattaneo E, Clevers H, Daley GQ, et al. Regulation of stem cell therapies under attack in Europe: for whom the bell tolls. EMBO J. 2013;32(11):1489\u201395. https:\/\/doi.org\/10.1038\/emboj.2013.114.","journal-title":"EMBO J"},{"issue":"10","key":"2435_CR41","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1056\/NEJMsr1715626","volume":"378","author":"P Marks","year":"2018","unstructured":"Marks P, Gottlieb S. Balancing safety and innovation for cell-based regenerative medicine. N Engl J Med. 2018;378(10):954\u20139. https:\/\/doi.org\/10.1056\/NEJMsr1715626.","journal-title":"N Engl J Med"},{"key":"2435_CR42","first-page":"514","volume":"376","author":"C. A. T. S. S","year":"2010","unstructured":"C. A. T. S. S. Committee for Advanced Therapies and, Use of unregulated stem-cell based medicinal products. Lancet. 2010;376:514.","journal-title":"Lancet"},{"key":"2435_CR43","unstructured":"FDA. 2020. https:\/\/www.fda.gov\/vaccines-blood-biologics\/consumers-biologics\/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes?utm_campaign=What%27sNew2020-07-22&utm_medium=email&utm_source=Eloqua Accessed 29 Oct 2020"},{"key":"2435_CR44","unstructured":"FDA. 2019. https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/warning-letters\/liveyon-labs-inc-588399-12052019. Accessed 29 Oct 2020"},{"key":"2435_CR45","unstructured":"FDA. 2020; Vol. 2020. https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/warning-letters\/invitrx-therapeutics-inc-581182-03162020. Accessed 29 Oct 2020"},{"issue":"1","key":"2435_CR46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nm.3028","volume":"19","author":"P Bianco","year":"2013","unstructured":"Bianco P, Cao X, Frenette PS, Mao JJ, Robey PG, Simmons PJ, et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med. 2013;19(1):35\u201342. https:\/\/doi.org\/10.1038\/nm.3028.","journal-title":"Nat Med"},{"key":"2435_CR47","doi-asserted-by":"publisher","unstructured":"P. Bianco, Mesenchymal\u201d stem cells. Annu Rev Cell Dev Biol 30, 677-704 (2014), 1, doi: https:\/\/doi.org\/10.1146\/annurev-cellbio-100913-013132.","DOI":"10.1146\/annurev-cellbio-100913-013132"},{"key":"2435_CR48","doi-asserted-by":"publisher","unstructured":"Robey PG. \u201cMesenchymal stem cells\u201d: fact or fiction, and implications in their therapeutic use [version 1; peer review: 2 approved]. F1000Research. 2017;6(F1000 Faculty Rev):524. https:\/\/doi.org\/10.12688\/f1000research.10955.1.","DOI":"10.12688\/f1000research.10955.1"},{"key":"2435_CR49","doi-asserted-by":"publisher","unstructured":"Fisher SA, Cutler A, Doree C, Brunskill SJ, Stanworth SJ, Navarrete C, et al. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition. Cochrane Database Syst Rev. 2019. https:\/\/doi.org\/10.1002\/14651858.CD009768.pub2.","DOI":"10.1002\/14651858.CD009768.pub2"},{"issue":"4","key":"2435_CR50","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315\u20137. https:\/\/doi.org\/10.1080\/14653240600855905.","journal-title":"Cytotherapy"},{"key":"2435_CR51","unstructured":"EDQM. Council of Europe. 2020. https:\/\/standardterms.edqm.eu\/. Accessed 02 Oct 2020."},{"key":"2435_CR52","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical computing; 2021.\u00a0https:\/\/www.R-project.org\/."},{"key":"2435_CR53","doi-asserted-by":"publisher","unstructured":"Wickham et al. Welcome to the tidyverse. J Open Sour Softw. 2019;4(43);1686. https:\/\/doi.org\/10.21105\/joss.01686.","DOI":"10.21105\/joss.01686"},{"issue":"2","key":"2435_CR54","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.stem.2014.01.013","volume":"14","author":"M Mendicino","year":"2014","unstructured":"Mendicino M, Bailey AM, Wonnacott K, Puri RK, Bauer SR. MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell. 2014;14(2):141\u20135. https:\/\/doi.org\/10.1016\/j.stem.2014.01.013.","journal-title":"Cell Stem Cell"},{"key":"2435_CR55","unstructured":"Barry F, et al. Mesenchymal stem cells: characterization, therapeutic evaluation and manufacturing. Eur Cells Mater. 2008;16(3):2."},{"issue":"7","key":"2435_CR56","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.3727\/096368912X657378","volume":"22","author":"Y Mifune","year":"2013","unstructured":"Mifune Y, Matsumoto T, Murasawa S, Kawamoto A, Kuroda R, Shoji T, et al. Therapeutic superiority for cartilage repair by CD271-positive marrow stromal cell transplantation. Cell Transplant. 2013;22(7):1201\u201311. https:\/\/doi.org\/10.3727\/096368912X657378.","journal-title":"Cell Transplant"},{"issue":"2","key":"2435_CR57","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3324\/haematol.13740","volume":"94","author":"VL Battula","year":"2009","unstructured":"Battula VL, Treml S, Bareiss PM, Gieseke F, Roelofs H, de Zwart P, et al. Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica. 2009;94(2):173\u201384. https:\/\/doi.org\/10.3324\/haematol.13740.","journal-title":"Haematologica"},{"key":"2435_CR58","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1182\/blood-2005-11-010504","volume":"109","author":"EJ Gang","year":"2006","unstructured":"Gang EJ, Bosnakovski D, Figueiredo CA, Visser JW, Perlingeiro RCR. SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood. 2006;109:1743\u201351.","journal-title":"Blood"},{"issue":"1","key":"2435_CR59","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13287-015-0266-z","volume":"7","author":"L Harkness","year":"2016","unstructured":"Harkness L, Zaher W, Ditzel N, Isa A, Kassem M. CD146\/MCAM defines functionality of human bone marrow stromal stem cell populations. Stem Cell Res Ther. 2016;7(1):4. https:\/\/doi.org\/10.1186\/s13287-015-0266-z.","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"2435_CR60","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3727\/096368912X656045","volume":"22","author":"YB Cho","year":"2013","unstructured":"Cho YB, Lee WY, Park KJ, Kim M, Yoo HW, Yu CS. Autologous adipose tissue-derived stem cells for the treatment of Crohn\u2019s fistula: a phase I clinical study. Cell Transplant. 2013;22(2):279\u201385. https:\/\/doi.org\/10.3727\/096368912X656045.","journal-title":"Cell Transplant"},{"issue":"6","key":"2435_CR61","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1161\/CIRCRESAHA.115.306332","volume":"117","author":"EC Perin","year":"2015","unstructured":"Perin EC, Borow KM, Silva GV, DeMaria AN, Marroquin OC, Huang PP, et al. A phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure. Circ Res. 2015;117(6):576\u201384. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306332.","journal-title":"Circ Res"},{"issue":"6","key":"2435_CR62","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jcyt.2013.02.006","volume":"15","author":"P Bourin","year":"2013","unstructured":"Bourin P, Bunnell BA, Casteilla L, Dominici M, Katz AJ, March KL, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal\/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy. 2013;15(6):641\u20138. https:\/\/doi.org\/10.1016\/j.jcyt.2013.02.006.","journal-title":"Cytotherapy"},{"issue":"1","key":"2435_CR63","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2174\/1874325001105010253","volume":"5","author":"P Mafi","year":"2011","unstructured":"Mafi P, Hindocha S, Mafi R, Griffin M, Khan W. Adult mesenchymal stem cells and cell surface characterization - a systematic review of the literature. Open Orthop J. 2011;5(1):253\u201360. https:\/\/doi.org\/10.2174\/1874325001105010253.","journal-title":"Open Orthop J"},{"key":"2435_CR64","unstructured":"Wagey R, Short B. Mesenchymal stem and progenitor cells: problems, potential and promise. J Stem Cells Res Rev Rep. 2014;1(3):1016."},{"key":"2435_CR65","doi-asserted-by":"publisher","unstructured":"Wilson A, Hodgson-Garms M, Frith JE, Genever P. Multiplicity of mesenchymal stromal cells: finding the right route to therapy. Frontiers in Immunology. 2019;10. https:\/\/doi.org\/10.3389\/fimmu.2019.01112.","DOI":"10.3389\/fimmu.2019.01112"},{"issue":"7","key":"2435_CR66","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1001\/jama.2014.17662","volume":"313","author":"JP Ioannidis","year":"2015","unstructured":"Ioannidis JP. Stealth research: is biomedical innovation happening outside the peer-reviewed literature? JAMA. 2015;313(7):663\u20134. https:\/\/doi.org\/10.1001\/jama.2014.17662.","journal-title":"JAMA"},{"issue":"4","key":"2435_CR67","doi-asserted-by":"publisher","first-page":"e13072","DOI":"10.1111\/eci.13072","volume":"49","author":"IA Cristea","year":"2019","unstructured":"Cristea IA, Cahan EM, Ioannidis JPA. Stealth research: lack of peer-reviewed evidence from healthcare unicorns. Eur J Clin Invest. 2019;49(4):e13072. https:\/\/doi.org\/10.1111\/eci.13072.","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"2435_CR68","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.5435\/JAAOS-D-18-00305","volume":"27","author":"CR Chu","year":"2019","unstructured":"Chu CR, Rodeo S, Bhutani N, Goodrich LR, Huard J, Irrgang J, et al. Optimizing clinical use of biologics in orthopaedic surgery: consensus recommendations from the 2018 AAOS\/NIH U-13 conference. J Am Acad Orthop Surg. 2019;27(2):e50\u201363. https:\/\/doi.org\/10.5435\/JAAOS-D-18-00305.","journal-title":"J Am Acad Orthop Surg"},{"issue":"416","key":"2435_CR69","doi-asserted-by":"publisher","first-page":"eaam7828","DOI":"10.1126\/scitranslmed.aam7828","volume":"9","author":"A Galleu","year":"2017","unstructured":"Galleu A, Riffo-Vasquez Y, Trento C, Lomas C, Dolcetti L, Cheung TS, et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci Transl Med. 2017;9(416):eaam7828. https:\/\/doi.org\/10.1126\/scitranslmed.aam7828.","journal-title":"Sci Transl Med"},{"key":"2435_CR70","doi-asserted-by":"publisher","unstructured":"Weiss DJ, English K, Krasnodembskaya A, Isaza-Correa JM, Hawthorne IJ, Mahon BP. The necrobiology of mesenchymal stromal cells affects therapeutic efficacy. Frontiers in Immunology. 2019;10. https:\/\/doi.org\/10.3389\/fimmu.2019.01228.","DOI":"10.3389\/fimmu.2019.01228"},{"key":"2435_CR71","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/stem.2779","volume":"36","author":"SFH de Witte","year":"2018","unstructured":"de Witte SFH, et al. immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells. Stem Cells. 2018;36:602\u201315.","journal-title":"Stem Cells"},{"key":"2435_CR72","unstructured":"PRISMA. 2020. http:\/\/www.prisma-statement.org\/Endorsement\/PRISMAEndorsers. Accessed 23 Sept 2020"},{"key":"2435_CR73","unstructured":"CONSORT. 2010. http:\/\/www.consort-statement.org\/. Accessed 23 Oct 2020"},{"issue":"mar23 1","key":"2435_CR74","doi-asserted-by":"publisher","first-page":"c869","DOI":"10.1136\/bmj.c869","volume":"340","author":"D Moher","year":"2010","unstructured":"Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340(mar23 1):c869. https:\/\/doi.org\/10.1136\/bmj.c869.","journal-title":"BMJ"},{"issue":"11","key":"2435_CR75","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.jclinepi.2005.12.020","volume":"59","author":"JJ Gagnier","year":"2006","unstructured":"Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, et al. Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration. J Clin Epidemiol. 2006;59(11):1134\u201349. https:\/\/doi.org\/10.1016\/j.jclinepi.2005.12.020.","journal-title":"J Clin Epidemiol"},{"issue":"15","key":"2435_CR76","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jama.285.15.1992","volume":"285","author":"D Moher","year":"2001","unstructured":"Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA. 2001;285(15):1992\u20135. https:\/\/doi.org\/10.1001\/jama.285.15.1992.","journal-title":"JAMA"},{"key":"2435_CR77","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/2046-4053-1-60","volume":"1","author":"L Turner","year":"2012","unstructured":"Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Syst Rev. 2012;1:60.","journal-title":"Syst Rev"},{"key":"2435_CR78","first-page":"1346026","volume":"2016","author":"M Johansen","year":"2016","unstructured":"Johansen M, Thomsen SF. Guidelines for reporting medical research: a critical appraisal. Int Sch Res Notices. 2016;2016:1346026.","journal-title":"Int Sch Res Notices"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-021-02435-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-021-02435-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-021-02435-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T12:21:07Z","timestamp":1624364467000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-021-02435-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2435"],"URL":"https:\/\/doi.org\/10.1186\/s13287-021-02435-1","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]},"assertion":[{"value":"29 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"360"}}